NLS Pharmaceutics (NLS Pharmaceutics) Cash-to-Debt : 0.55 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NLS Pharmaceutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.55.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, NLS Pharmaceutics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for NLS Pharmaceutics's Cash-to-Debt or its related term are showing as below:

NLSP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 1.79 Max: No Debt
Current: No Debt

During the past 7 years, NLS Pharmaceutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 1.79.

NLSP's Cash-to-Debt is ranked better than
99.8% of 1535 companies
in the Biotechnology industry
Industry Median: 6.49 vs NLSP: No Debt

NLS Pharmaceutics Cash-to-Debt Historical Data

The historical data trend for NLS Pharmaceutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NLS Pharmaceutics Cash-to-Debt Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.26

0.05

No Debt

0.55

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial								No Debt	3.83	No Debt	No Debt	0.55

Competitive Comparison of NLS Pharmaceutics's Cash-to-Debt

For the Biotechnology subindustry, NLS Pharmaceutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Cash-to-Debt falls into.

NLS Pharmaceutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NLS Pharmaceutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.898	/	(1.634	+	0)
	=	0.55

NLS Pharmaceutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.898	/	(1.634	+	0)
	=	0.55

NLS Pharmaceutics (NAS:NLSP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NLS Pharmaceutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.